Last reviewed · How we verify
NCT06299020
Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency
NA trial testing intermittent fasting in Primary Adrenal Insufficiency in 30 participants. Completed in 1 December 2024.
20 April 2024
Quick facts
| Lead sponsor | Hopital La Rabta |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 4 March 2024 |
| Primary completion | 20 April 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across Tunisia |
Drugs / interventions tested
- intermittent fasting
Conditions studied
- Primary Adrenal Insufficiency — all drugs for Primary Adrenal Insufficiency →
- Intermittent Fasting — all drugs for Intermittent Fasting →
Sponsor
Hopital La Rabta — full company profile →
Who can join
Adults 20 to 65, any sex, with Primary Adrenal Insufficiency or Intermittent Fasting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In primary adrenal insufficiency, there is an increased risk of hypoglycaemia and dehydration. These risks have been little studied particularly during intermittent fasting. The present study aimed to assess these risks in a prospective study of 30 subjects with primary adrenal insufficiency. Patients will undergo a clinical examination, blood sampling and continuous glucose monitoring for fourteen days (one week of fasting and one week of non-fasting).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hypoglycaemia and other risks of ramadan fasting in patients with primary adrenal insufficiency: A prospective controlled trial using 24-hour glucose monitoring.
Chihaoui M, Sta J, Kamoun E, Belhadjsliman C, et al · · 2026 · PMID 41108503 · DOI 10.1007/s40618-025-02728-9
Verify or expand the search:
- PubMed search for NCT06299020
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of intermittent fasting
Trials testing the same drug.
- NCT07513116 — Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening · NA · not yet recruiting
- NCT07385716 — Evaluation of the Effect of Time-Restricted Feeding and Mediterranean Diet Model in Women With Polycystic Ovary Syndrome · NA · recruiting
- NCT06893913 — Effect of Addition of Pyramidal Exercise to Intermittent Fasting on Dryness of Eye in Pre-diabetic Psoriasis Patients · NA · recruiting
- NCT06834256 — Intermittent Fasting vs. High-intensity Interval Training on the Lipid Profile of Obese Individuals. · NA · completed
- NCT06174259 — Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients · NA · unknown
Other Hopital La Rabta trials
Trials by the same sponsor.
- NCT07367425 — Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone. · NA · not yet recruiting
- NCT06832566 — Ramadan Fasting Outcomes in Patients With Secondary Adrenal Insufficiency Before and After the Treatment of Hypotension. · Phase 4 · not yet recruiting
- NCT05827965 — Ramadan Fasting in Secondary Adrenal Insufficiency Patients · NA · completed
- NCT05806723 — Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06299020 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hopital La Rabta
- Last refreshed: 14 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06299020.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing